Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473746 · ClinicalTrials.gov registry record · Phase 1
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00473746: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT00473746 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 66 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00473746, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
Primary Outcome
The MTD is the highest dose of a drug or treatment that does not cause unacceptable side effects.
Interventions
- DRUG Abiraterone acetate
- DRUG prednisone/prednisolone or dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT00473746 record still lists
NCT00473746 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% higher).
The record links to 0 conditions, and to 2 interventions - of which Abiraterone acetate is the first listed.
NCT00473746 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00473746 about?
NCT00473746 is a clinical study titled "Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer". The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
What is the current status of trial NCT00473746?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2006-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00473746?
The interventions under investigation include: Abiraterone acetate (DRUG), prednisone/prednisolone or dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00473746?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00473746's enrollment target sits among peer trials
66 786th of 2000 higher than 1,203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia